Colorectal cancer in ulcerative colitis after liver transplantation for primary sclerosing cholangitis: a systematic review and pooled analysis of oncological outcomes

IntroductionPatients with ulcerative colitis (UC) receiving liver transplantation (LT) due to primary sclerosing cholangitis (PSC) have higher risk of developing colorectal cancers (CRC). aim of this systematic review was to define the patients' features, immunosuppressive management, and oncological outcomes of LT recipients with UC-PSC developing CRC. methods searches were conducted in pubmed (MEDLINE), cochrane Library, web of Science for all english articles published until september 2023. Inclusion criteria were original articles including patients specifying outcomes of interest. primary endpoints comprised incidence of CRC, disease free survival (DFS), overall survival (OS) and cancer recurrence. Secondary endpoints were patient's and tumor characteristics, graft function, immunosuppressive management and PSC recurrence. PROSPERO CRD42022369190. results fifteen studies included, 88 patients were identified. patients (mean age: 50 years) had a long history of UC (20 years), mainly with active colitis (79%), and developed tumor within the first 3 years from LT, while receiving a double or triple immunosuppressive therapy. cumulative incidence of tumor was 5.5%. at one, two and three years, DFS was 92%, 82% and 75%, while OS was 87%, 81% and 79% respectively. disease progression rate was 15%. after CRC surgery, 94% of patients maintained a good graft functionality, with no reported cases of PSC recurrence. conclusionsAfter LT, patients with PSC and UC have an increased risk of CRC, especially in presence of long history of UC and active colitis. surgical resection guarantees satisfactory mid-term oncological outcomes, but samples are limited, and long-term data are lacking. national and international registry are auspicial to evaluate long-term oncological outcomes and to optimize clinical management.